GlassScriptPhysician profile
Rena Hamazaspyan
NPI 1124391057
$2,571.23
in general payments reported to CMS, 2019-2025
24 companies · $942 in 2025
The $942 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $261 · 2023: $347 · 2024: $716 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $309.41 | 2022-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $268.44 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $239.07 | 2021-2025 | |
| Boston Scientific Corporation | $178.02 | 2023-2024 | Watchman Flx, Watchman Access System |
| Alnylam Pharmaceuticals INC. | $176.26 | 2025 | Amvuttra, Onpattro |
| Pfizer INC. | $161.42 | 2021-2025 | |
| Esperion Therapeutics, INC. | $152.40 | 2021-2022 | |
| Heartflow, INC. | $147.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.04 | 2024 | |
| Gilead Sciences, INC. | $117.13 | 2025 | Descovy |
| Medtronic, INC. | $112.89 | 2025 | Corevalve Evolut R |
| Amgen INC. | $106.03 | 2021-2022 | |
| Inspire Medical Systems, INC. | $90.25 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $59.98 | 2024-2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $53.99 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $44.49 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $43.62 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $39.34 | 2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $38.66 | 2024 | Optimizer |
| Astellas Pharma US INC | $28.72 | 2021 | |
| Abiomed | $25.73 | 2023 | Impella |
| Abbott Laboratories | $23.18 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Hamazaspyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.